Description

Erlotinib-13C6 (hydrochloride) is the 13C labeled Erlotinib Hydrochloride[1]. Erlotinib Hydrochloride (CP-358774 Hydrochloride) inhibits purified EGFR kinase with an IC50 of 2 nM[2]. Erlotinib-13C6 (hydrochloride) is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.–Applications-Cancer-Kinase/protease-Formula-C16 13C6H24ClN3O4-Citation–References-[1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53(2):211-216.|[2]Moyer JD, et al. Induction of apoptosis and cell cycle arrest by CP-358,774, an inhibitor of epidermal growth factor receptor tyrosine kinase. Cancer Res. 1997 Nov 1;57(21):4838-48.-CASNumber-1210610-07-3-MolecularWeight-435.85-Compound Purity–SMILES-COCCOC(C(OCCOC)=C1)=CC2=C1C(N[13C]3=[13CH][13C](C#C)=[13CH][13CH]=[13CH]3)=NC=N2.Cl-Research_Area-Cancer-Solubility-10 mM in DMSO-Target-Autophagy;EGFR-Isoform–Pathway-Autophagy;JAK/STAT Signaling;Protein Tyrosine Kinase/RTK-MCE Product type-Isotope-Labeled Compounds